gemcitabine

Open Access
Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma In Vitro and In Vivo
PRIN SUNGWAN, SONEXAI KIDOIKHAMMOUAN, UNCHALEE THONSRI, CHARUPONG SAENGBOONMEE, SOPIT WONGKHAM, SEIJI OKADA and WUNCHANA SEUBWAI

In Vivo September 2024, 38 (5) 2284-2293; DOI: https://doi.org/10.21873/invivo.13693
Open Access
Flavokawain B Inhibits Growth of Cholangiocarcinoma Cells by Suppressing the Akt Pathway
JUN HYUK SON, YOUNG HOON CHOI, SANG HYUB LEE, WOO HYUN PAIK, JI KON RYU and YONG-TAE KIM

In Vivo May 2023, 37 (3) 1077-1084; DOI: https://doi.org/10.21873/invivo.13182
You have access
The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells
DAISUKE NAMIMA, SHINTARO FUJIHARA, HISAKAZU IWAMA, KOJI FUJITA, TAKANORI MATSUI, MAI NAKAHARA, MEGUMI OKAMURA, MASAHIRO HIRATA, TOSHIAKI KONO, NAOKI FUJITA, HIROKI YAMANA, KIYOHITO KATO, HIDEKI KAMADA, ASAHIRO MORISHITA, HIDEKI KOBARA, KUNIHIKO TSUTSUI and TSUTOMU MASAKI

In Vivo November 2020, 34 (6) 3195-3203; DOI: https://doi.org/10.21873/invivo.12155
You have access
Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma
TAKASHI SUZUKI, SHOZO MORI, TAKAYUKI SHIMIZU, KAZUMA TAGO, NOBUHIRO HARADA, KYUNG-HWA PARK, YUHKI SAKURAOKA, TAKAYUKI SHIRAKI, YUKIHIRO ISO, TAKU AOKI and KEIICHI KUBOTA

In Vivo November 2019, 33 (6) 2027-2035; DOI: https://doi.org/10.21873/invivo.11700
You have access
Four-weekly Low-dose Gemcitabine and Paclitaxel in Patients With Platinum-resistant Urothelial Cancer and Performance Status 2/3
KYOHEI ARAKI, YASUYOSHI MIYATA, YUICHIRO NAKAMURA, YUTA MUKAE, ASATO OTSUBO, TSUTOMU YUNO, KENSUKE MITSUNARI, TOMOHIRO MATSUO, KOJIRO OHBA and HIDEKI SAKAI

In Vivo November 2019, 33 (6) 2217-2224; DOI: https://doi.org/10.21873/invivo.11725
You have access
shRNA-WT1 Potentiates Anticancer Effects of Gemcitabine and Cisplatin Against B16F10 Lung Metastases In Vitro and In Vivo
PABLO ZAPATA-BENAVIDES, FERNANDA GUADALUPE THOMPSON-ARMENDARIZ, MARIELA ARELLANO-RODRÍGUEZ, MOISÉS ARMIDES FRANCO-MOLINA, EDGAR MENDOZA-GAMBOA, SANTIAGO SAAVEDRA-ALONSO, JOSÉ LUIS ZACARIAS-HERNÁNDEZ, LAURA MARÍA TREJO-AVILA and CRISTINA RODRÍGUEZ-PADILLA

In Vivo May 2019, 33 (3) 777-785; DOI: https://doi.org/10.21873/invivo.11539
You have access
Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis
TAKASHI SASAKI, RYO KANATA, IKUHIRO YAMADA, MASATO MATSUYAMA, MASATO OZAKA and NAOKI SASAHIRA

In Vivo January 2019, 33 (1) 271-276; DOI: https://doi.org/10.21873/invivo.11471
You have access
R0 Resection for Locally Advanced Pancreatic Cancer with Low-dose Gemcitabine with Wide Irradiation Area as Neoadjuvant Chemoradiotherapy
HIROFUMI KAMACHI, YOUSUKE TSURUGA, TATSUYA ORIMO, KENJI WAKAYAMA, SHINGO SHIMADA, AKIHISA NAGATSU, HIDEKI YOKOO, TOSHIYA KAMIYAMA, NORIO KATOH and AKINOBU TAKETOMI

In Vivo September 2018, 32 (5) 1183-1191; DOI: https://doi.org/10.21873/invivo.11362
You have access
Heat Shock Protein 27 Expression in EUS-FNA Samples Can Predict Gemcitabine Sensitivity in Pancreatic Cancer
MICHITAKA KAWANO, SEIJI KAINO, SHOGO AMANO, SHUHEI SHINODA, SHIGEYUKI SUENAGA, MANABU SEN-YO and ISAO SAKAIDA

In Vivo May 2018, 32 (3) 637-642;
You have access
Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer
STEFANIA KOKKALI, ELLI-SOPHIA TRIPODAKI, MARIA DRIZOU, DIMITRA STEFANOU, ELPIDA MAGOU, DIMOSTHENIS ZYLIS, MATTHAIOS KAPIRIS, DESPOINA NASI, CHARA GEORGANTA and ALEXANDROS ARDAVANIS

In Vivo May 2018, 32 (3) 653-657;

Main menu

User menu

Search

gemcitabine

Pages